Abstract
Thromboembolic disorders are still the leading causes of morbidity and mortality in developed societies. Therefore, prophylaxis and treatment of arterial and venous thrombosis are among the main therapeutic challenges nowadays. Simultaneous action on several targets involved in pathology of thrombosis offers potential advantages compared to existing drugs which were developed as selective modulators of single targets. The review focuses on dual inhibitors of coagulation enzymes, dual antiaggregatory compounds exerting their action on different combinations of platelet targets, as well as on anticoagulant/antiaggregatory compounds which interfere with at least one target involved in blood coagulation and at least one target engaged in the process leading to platelet aggregation.
Keywords: Anticoagulants, antiplatelet, antithrombotics, dual inhibitors, multitarget drugs, prophylaxis, anticoagulant/antiaggregatory compounds, haemostasis, antiplatelet activity, antiaggregatory drugs, calcium ions, coagulation factors, pharmacokineticproperties, predictable pharmacokinetics, thromboxane synthase
Current Topics in Medicinal Chemistry
Title: Multitarget Antithrombotic Drugs
Volume: 11 Issue: 22
Author(s): Milos Ilic, Danijel Kikelj and Janez Ilas
Affiliation:
Keywords: Anticoagulants, antiplatelet, antithrombotics, dual inhibitors, multitarget drugs, prophylaxis, anticoagulant/antiaggregatory compounds, haemostasis, antiplatelet activity, antiaggregatory drugs, calcium ions, coagulation factors, pharmacokineticproperties, predictable pharmacokinetics, thromboxane synthase
Abstract: Thromboembolic disorders are still the leading causes of morbidity and mortality in developed societies. Therefore, prophylaxis and treatment of arterial and venous thrombosis are among the main therapeutic challenges nowadays. Simultaneous action on several targets involved in pathology of thrombosis offers potential advantages compared to existing drugs which were developed as selective modulators of single targets. The review focuses on dual inhibitors of coagulation enzymes, dual antiaggregatory compounds exerting their action on different combinations of platelet targets, as well as on anticoagulant/antiaggregatory compounds which interfere with at least one target involved in blood coagulation and at least one target engaged in the process leading to platelet aggregation.
Export Options
About this article
Cite this article as:
Ilic Milos, Kikelj Danijel and Ilas Janez, Multitarget Antithrombotic Drugs, Current Topics in Medicinal Chemistry 2011; 11 (22) . https://dx.doi.org/10.2174/156802611798184364
DOI https://dx.doi.org/10.2174/156802611798184364 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Soy Isoflavones and Cardiovascular Health: An Update
Current Nutrition & Food Science Molecular Recognition Mechanisms for Detecting Cell Death In Vivo
Current Pharmaceutical Biotechnology Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Preface: MicroRNA as Disease Biomarkers
MicroRNA Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design L-Arginine Transport in Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
Current Drug Targets Antioxidative Properties of Flavonoids
Current Organic Chemistry Myogenic Potential of Mesenchymal Stem Cells - the Case of Adhesive Fraction of Human Umbilical Cord Blood Cells
Current Stem Cell Research & Therapy Relevance of Postprandial Lipemia in Metabolic Syndrome
Current Vascular Pharmacology Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Exciting News from the Messenger
Current Neurovascular Research Carbohydrates in Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Physiological and Pharmacological Insights into the Role of Ionic Channels in Cardiac Pacemaker Activity
Cardiovascular & Hematological Disorders-Drug Targets The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Bone Loss and Osteoporosis are Associated with Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research